MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
0.7773
-0.0420
-5.13%
After Hours: 0.7840 +0.0067 +0.86% 19:45 02/09 EST
OPEN
0.8330
PREV CLOSE
0.8193
HIGH
0.8330
LOW
0.7406
VOLUME
635.75K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
0.6844
MARKET CAP
24.92M
P/E (TTM)
-0.6027
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SKYE last week (0202-0206)?
Weekly Report · 20h ago
Analysts’ Top Healthcare Picks: Aquestive Therapeutics (AQST), Skye Bioscience (SKYE)
TipRanks · 02/02 19:10
Analysts Are Bullish on Top Healthcare Stocks: Doximity (DOCS), Skye Bioscience (SKYE)
TipRanks · 02/02 19:00
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating
TipRanks · 02/02 18:35
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year
Benzinga · 02/02 18:26
Skye Bioscience Reports Promising Phase 2a Obesity Data
TipRanks · 02/02 12:35
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab
TipRanks · 02/02 12:26
Skye Reports Phase 2a Extension Results Showing 22.3% Weight Loss At 52 Weeks With Nimacimab And Semaglutide Combination
Benzinga · 02/02 12:22
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.